A Multicentre, Adaptive, Randomised, Multidomain, Platform Trial for Dose Optimization in the Treatment of Adult Patients With Haematological Diseases (BLOOD-dose): Core Protocol
Latest Information Update: 26 Mar 2026
At a glance
- Drugs Elranatamab (Primary) ; Ibrutinib (Primary) ; Linvoseltamab (Primary) ; Talquetamab (Primary) ; Teclistamab (Primary) ; Zanubrutinib (Primary)
- Indications Multiple myeloma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- Acronyms BELLIS domain; Core protocol:BLOOD-Dose; ElasTEC domain
Most Recent Events
- 26 Mar 2026 New trial record